Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Top Cited Papers
Open Access
- 15 May 2014
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 123 (20), 3073-3079
- https://doi.org/10.1182/blood-2014-01-550020
Abstract
We assessed the prognostic value of minimal residual disease (MRD) detection in multiple myeloma (MM) patients using a sequencing-based platform in bone marrow samples from 133 MM patients in at least very good partial response (VGPR) after front-line therapy. Deep sequencing was carried out in patients in whom a high-frequency myeloma clone was identified and MRD was assessed using the IGH-VDJH, IGH-DJH, and IGK assays. The results were contrasted with those of multiparametric flow cytometry (MFC) and allele-specific oligonucleotide polymerase chain reaction (ASO-PCR). The applicability of deep sequencing was 91%. Concordance between sequencing and MFC and ASO-PCR was 83% and 85%, respectively. Patients who were MRD– by sequencing had a significantly longer time to tumor progression (TTP) (median 80 vs 31 months; P < .0001) and overall survival (median not reached vs 81 months; P = .02), compared with patients who were MRD+. When stratifying patients by different levels of MRD, the respective TTP medians were: MRD ≥10−3 27 months, MRD 10−3 to 10−5 48 months, and MRD −5 80 months (P = .003 to .0001). Ninety-two percent of VGPR patients were MRD+. In complete response patients, the TTP remained significantly longer for MRD– compared with MRD+ patients (131 vs 35 months; P = .0009).This publication has 51 references indexed in Scilit:
- Detection of circulating tumour DNA in patients with aggressive B‐cell non‐Hodgkin lymphomaBritish Journal of Haematology, 2013
- Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemiaLeukemia, 2013
- Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemiaBlood, 2012
- Has MRD monitoring superseded other prognostic factors in adult ALL?Blood, 2012
- Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemiaBlood, 2012
- Long-term prognostic significance of response in multiple myeloma after stem cell transplantationBlood, 2011
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBlood, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug ResistanceCancer Research, 2008
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998